| Autor: |
Martínez-Milla, Juan, García, Marcelino Cortés, Palfy, Julia Anna, Urquía, Mikel Taibo, Castillo, Marta López, Arbiol, Ana Devesa, Monteagudo, Ana Lucía Rivero, Mariscal, María Luisa Martín, Jiménez-Varas, Inés, Figuero, Sem Briongos, Franco-Pelaéz, Juan Antonio, Tuñón, José |
| Předmět: |
|
| Zdroj: |
Journal of Geriatric Cardiology; 2021, Vol. 18 Issue 1, p20-29, 10p |
| Abstrakt: |
OBJECTIVE•To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years. METHODS AND RESULTS•From January 2008 to July 2014, we included 390 consecutive patients ≥ 75 years of age with ejection fraction ≤ 35% and glomerular filtration rate (GFR) ≤ 60 mL/min per 1.73 m². We analyzed the relationship between treatment with BB and mortality or cardiovascular events. The mean age of our population was 82.6 ± 4.1 years. Mean ejection fraction was 27.9% ± 6.5%. GFR was 60-45 mL/min per 1.73 m² in 50.3% of patients, 45-30 mL/min per 1.73 m² in 37.4%, and < 30 mL/min per 1.73 m² in 12.3%. At the conclusion of follow-up, 67.4% of patients were receiving BB. The median follow-up was 28.04 (IR: 19.41-36.67) months. During the study period, 211 patients (54.1%) died and 257 (65.9%) had a major cardiovascular event (death or hospitalization for heart failure). BB use was significantly associated with a reduced risk of death (HR = 0.51, 95% CI: 0.35-0.74; P < 0.001). Patients receiving BB consistently showed a reduced risk of death across the different stages of CKD: stage IIIa (GFR = 30-45 mL/min per 1.73 m²; HR = 0.47, 95% CI: 0.26-0.86, P < 0.000 1), stage IIIb (GFR 30-45 mL/min per 1.73 m²; HR = 0.55, 95% CI: 0.26-1.06, P = 0.007), and stages IV and V (GFR < 30 mL/min per 1.73 m²; HR = 0.29, 95% CI: 0.11-0.76; P = 0.047). CONCLUSIONS•The use of BB in elderly patien [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
